The people who deserve extra attention usually include: Patients with a known history of diabetic retinopathy Patients with diabetic macular edema Patients with recently worsening retinopathy Patients with poor baseline glucose control who may experience a large A1c drop Patients starting semaglutide while already under retina treatment Patients with multiple high-risk features such as kidney disease, hypertension, or long-standing diabetes In contrast, a patient with type 2 diabetes, no known retinopathy, and a recent normal dilated exam may still need routine follow-upbut often not the same level of concern as someone with active retinal disease
This publication does not endorse, vouch for, audit, or accept responsibility for the accuracy, completeness, or fairness of customer reviews posted on any third-party platform, including general-purpose review sites, social media platforms, and online discussion forums
Further, the process of the present invention provides advantages, such as environmental friendliness due to the use of an immobilized enzyme in the preparation of the intermediate, and applicability thereof to industrial-scale production arising from decreased production costs due to the recyclability of the enzyme
Journal of Nanotheranostics
10.1007/s12264-020-00620-5 19 CaraballoR
